by adminAdrianRamirez | Oct 14, 2017 | Media Coverage
A chewing gum developed by AXIM delivers CBD and other crucial cannabinoids A recent article published in LinkedIn’s Healthcare section on the current U.S. opioid addiction crisis focused on ways doctors themselves are trying to combat the growing epidemic. The...
by adminAdrianRamirez | Aug 3, 2017 | Axim Biotechnologies, Press Releases
SAN DIEGO, Aug. 3, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical...
by adminAdrianRamirez | Jul 27, 2017 | Axim Biotechnologies, Press Releases
SAN DIEGO, July 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services...
by adminAdrianRamirez | Jul 20, 2017 | Axim Biotechnologies, Press Releases
AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...
by adminAdrianRamirez | Jun 27, 2017 | Axim Biotechnologies, Press Releases
NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in...